Frequently Asked Questions

Convenient

May reduce the number of injections you give infants and children

Administer this 4-dose DTaP-IPV/Hib vaccine and simplify your immunization schedule2,3

Pentacel vaccine fits the recommended immunization schedule2,3
Pentacel vaccine contains a Hib component and fits easily into the primary series at 2, 4, and 6 months of age, with a booster at 15-18 months of age.1 Children who have completed the 4-dose series with Pentacel vaccine should receive a fifth dose of DTaP at 4-6 years of age.2

Pentacel vaccine may enhance compliance
Administering a combination such as Pentacel vaccine may enhance timeliness and compliance at the fourth dose.3,4 This is important because a 2009 National Immunization Survey showed that by 24 months of age, 1 in 5 children did not receive all 4 recommended doses of DTaP vaccine.5

  • Image of chart: Adapted From the Recommended Immunization Schedule for Persons Aged 0 Through 6 Years-United States, 2011
  • Image of chart: Impact of Pentacel Vaccine on the Immunization Schedule

Image of Chart: Adapted From the Recommended Immunization Schedule for Persons Aged 0 Through 6 Years-United States, 2011
Image of Chart: Impact of Pentacel Vaccine on the Immunization Schedule
Image of chart


Indication
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).


Safety Information
The most common local and systemic adverse reactions to Pentacel vaccine include injection site redness, swelling, and tenderness; fever, fussiness, and crying. Other adverse reactions may occur. Known systemic hypersensitivity reaction to any component of Pentacel vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances are contraindications to vaccination.

The decision to give Pentacel vaccine should be based on the potential benefits and risks; if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; or if adverse events have occurred in temporal relation to receipt of pertussis-containing vaccine. Encephalopathy within 7 days of administration of a previous dose of a pertussis-containing vaccine or a progressive neurologic disorder is a contraindication. Vaccination with Pentacel vaccine may not protect all individuals.

Before administering Pentacel vaccine, please see the full Prescribing Information.

Pentacel vaccine is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA and distributed by Sanofi Pasteur Inc.

Image of Send to a Friend
Image of Share This Page
Image of Print Page